Under the deal, Catalent will provide manufacturing services for an initial 100 million doses starting in the third quarter at its facility in Bloomington, Indiana. It will also provide other packaging and labeling, storage and distribution services at its facilities in Philadelphia, Pennsylvania to support Moderna’s late-stage vaccine trial, which is expected to begin in July. Drugmakers including Johnson & Johnson and AstraZeneca Plc have also signed agreements to boost manufacturing capacity for their experimental vaccines even before having adequate evidence of their efficacy. …read more
Source:: Yahoo Finance
